08 August 2022: Clinical Research
Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
Beatriz Barranco-Fragoso 12ABC , Shreya C. Pal 34CDEFG , Luis E. Díaz-Orozco 34ABCDEF , Rita Dorantes-Heredia 5BCD , Xingshun Qi 6F , Nahum Méndez-Sánchez 34ACDEF*DOI: 10.12659/MSM.937528
Med Sci Monit 2022; 28:e937528
Table 3 Hepatic dendritic cells’ (CD11c+) expression in MAFLD according to patients’ BMI and either presence or absence of fibrosis:The findings of liver fibrosis among different weight groups was variable, finding that the most marked difference is dependent on the number of patients in each group (eg, non-obese patients constitute a lower percentage of the population, for which they constitute a lower percentage of patients with fibrosis, as well as without fibrosis).
| Patients with MAFLD (n=128) | Hepatic dendritic cells (CD11c+) N (%) 72 |
|---|---|
| Morbidly obese patients with no fibrosis (n=44) | 29 (65.91) |
| Morbidly obese patients with fibrosis (n=32) | 20 (62.50) |
| Patients with obesity grade I–II and no fibrosis (n=13) | 8 (61.54) |
| Patients with obesity grade I–II and fibrosis (n=20) | 10 (50.00) |
| Non-obese patients with no fibrosis (n=7) | 2 (28.57) |
| Non-obese patients with fibrosis (n=12) | 3 (25.00) |
| BMI – body mass index; MAFLD – metabolic (dysfunction)-associated fatty liver disease. | |